.
MergerLinks Header Logo

New Deal


Announced

Completed

Shiyu Capital led a $278m Series A round for Mabwell BioScience.

Synopsis

Private equity firm Shenzhen Shiyu Investment Management led a $278m Series A round for Mabwell BioScience, a biopharmaceutical firm. Oriental Fortune Capital, Loyal Valley Innovation Capital, Haitong Innovation Capital Management, Founder H Fund, Haurong Rongde Asset Management, Huajin Capital, Sincere Capital, Winfast Holding and other investors also participated in the new round. “The fundraising amount has exceeded our initial expectation. Under a critical time when the COVID-19 pandemic has swept across the world, we managed to obtain the trust from many professional institutional investors including Shiyu Capital, as well as funds with links to China’s Ministry of Finance, Ministry of Science and Technology, among other backgrounds," Liu Datao, Mabwell President.

Show Details & Financials

Market Context

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US